- Trials with a EudraCT protocol (158)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
158 result(s) found for: Foam Cell.
Displaying page 1 of 8.
EudraCT Number: 2017-004451-24 | Sponsor Protocol Number: HC-ENS-2017-01 | Start Date*: 2018-01-23 |
Sponsor Name:Fundació Clínic per a la Reserca Biomèdica | ||
Full Title: Phase IV, unicentric, open-label, randomized clinical trial to evaluate clinic and non-invasive response to clobetasol cream versus betamethasone dipropionate and calcipotriol foam treatments in pl... | ||
Medical condition: Plaque psoriasis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002579-83 | Sponsor Protocol Number: 54767414LUC2001 | Start Date*: 2017-02-24 | ||||||||||||||||
Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||
Full Title: A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic N... | ||||||||||||||||||
Medical condition: Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) HU (Completed) FR (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-020916-12 | Sponsor Protocol Number: OSI-906-205 | Start Date*: 2011-03-15 | |||||||||||||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. | |||||||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI 906 plus Erlotinib (Tarceva®), or Erlotinib plus Placebo in Patients with Nonprogression Following Four Cycles of 1st... | |||||||||||||||||||||||
Medical condition: Non-small cell lung cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002894-39 | Sponsor Protocol Number: 8273-CL-0302 | Start Date*: 2016-03-11 | ||||||||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. | ||||||||||||||||||
Full Title: An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating M... | ||||||||||||||||||
Medical condition: Non-small Cell Lung Cancer Tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) DE (Prematurely Ended) NL (Prematurely Ended) ES (Temporarily Halted) PT (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000974-25 | Sponsor Protocol Number: 61186372NSC2005 | Start Date*: 2023-04-12 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Evaluation of Amivantamab Infusion Related Reaction Mitigation | |||||||||||||
Medical condition: EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001371-20 | Sponsor Protocol Number: 18-PP-03 | Start Date*: 2018-06-11 | |||||||||||
Sponsor Name:CHU de Nice | |||||||||||||
Full Title: Study of the role of local treatments on the modulation of the microbiome in psoriatic skin | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000106-41 | Sponsor Protocol Number: CXA100750 | Start Date*: 2004-09-07 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A study to investigate the effect of GW406381 on methotrexate pharmacokinetics in patients treated with methotrexate for rheumatoid arthritis | ||
Medical condition: The patients entering the trial have rheumatoid arthritis although treatment of the disease itself is not under investigation in this study. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-004231-38 | Sponsor Protocol Number: 08-BO-VIBH | Start Date*: 2009-01-26 | |||||||||||
Sponsor Name:Department of Medicine I, University Hospital St.Josef-Hospital, Ruhr University Bochum | |||||||||||||
Full Title: Effects of vildagliptin (Galvus®) on beta-cell function and turnover in humans | |||||||||||||
Medical condition: Diabetes mellitus, beta-cell function before and after pancreatic surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002144-42 | Sponsor Protocol Number: VEG111128 | Start Date*: 2009-05-26 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline R&D Limited | ||||||||||||||||||
Full Title: A Phase II, randomised, multicentre study to evaluate the efficacy and safety of pazopanib in combination with pemetrexed versus cisplatin plus pemetrexed, as first-line therapy in subjects with st... | ||||||||||||||||||
Medical condition: Histologically- or cytologically-confirmed diagnosis of non-predominantly squamous cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLC | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) DK (Completed) IT (Completed) NL (Completed) FR (Completed) ES (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-004014-17 | Sponsor Protocol Number: FIL_GA101_DHAP | Start Date*: 2014-08-04 | |||||||||||
Sponsor Name:Fondazione Italiana Linfomi ONLUS | |||||||||||||
Full Title: Phase II study with Ga101-DHAP as induction therapy in relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) patients before High-Dose chemotherapy BEAM with autologous stem cell transplantatio... | |||||||||||||
Medical condition: Young patients with DLBCL who failed or relapsed after one previous chemotherapy regimen. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012280-34 | Sponsor Protocol Number: 26866138-LYM-2034 | Start Date*: 2009-12-04 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, ... | |||||||||||||
Medical condition: Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) PT (Completed) CZ (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010571-24 | Sponsor Protocol Number: VEG111109 | Start Date*: 2009-08-03 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||||||||||||||||||
Full Title: An open label, multicenter, Phase I/II study of pazopanib in combination with paclitaxel in first line treatment of subjects with stage IIIBwet/IV non-small cell lung cancer | ||||||||||||||||||
Medical condition: Part I: Subjects with histologically or cytologically confirmed diagnosis of advanced solid tumours for which there is no standard therapy or for whom paclitaxel is standard therapy. Part II: Sta... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003506-11 | Sponsor Protocol Number: IFCT-1703 | Start Date*: 2019-01-23 | |||||||||||||||||||||
Sponsor Name:IFCT | |||||||||||||||||||||||
Full Title: Phase II trial of trastuzumab in combination with pertuzumab in pretreated patients with non-small cell lung cancer (NSCLC) harboring a Her2 mutation and receiving docetaxel | |||||||||||||||||||||||
Medical condition: Non small cell lung cancer with a Her2 mutation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001985-41 | Sponsor Protocol Number: 09-09 | Start Date*: 2013-08-27 | |||||||||||
Sponsor Name:Onconova Therapeutics Inc. | |||||||||||||
Full Title: A Phase II Study of Oral Rigosertib in Patients with Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma | |||||||||||||
Medical condition: Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000633-40 | Sponsor Protocol Number: 61186372NSC3001 | Start Date*: 2020-11-18 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced... | |||||||||||||
Medical condition: EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) FR (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019484-10 | Sponsor Protocol Number: E7080-G000-205 | Start Date*: 2011-07-18 | ||||||||||||||||
Sponsor Name:Eisai Ltd | ||||||||||||||||||
Full Title: An open-label, multicenter Phase Ib/2 study of E7080 alone, and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-tar... | ||||||||||||||||||
Medical condition: Unresectable Advanced or Metastatic Renal Cell Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) CZ (Completed) PL (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001013-89 | Sponsor Protocol Number: DAMTE | Start Date*: 2018-08-28 | ||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERA "BIANCHI-MELACRINO-MORELLI" | ||||||||||||||||||
Full Title: Double ASCT in MM: phase III study comparing between melphalan based regimen vs a new regimen consisting of melphalan and thiotepa | ||||||||||||||||||
Medical condition: multiple myeloma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000743-31 | Sponsor Protocol Number: 73841937NSC3003 | Start Date*: 2020-09-23 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR Mutated Locally Advanced or Metastat... | |||||||||||||
Medical condition: EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) PT (Ongoing) HU (Ongoing) PL (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022770-13 | Sponsor Protocol Number: ICORG10-01 | Start Date*: 2011-01-12 | |||||||||||
Sponsor Name:Cancer Trials Ireland | |||||||||||||
Full Title: A phase II study of pazopanib in patients with metastatic or unresectable renal cell carcinoma (RCC) who have failed prior sunitinib therapy | |||||||||||||
Medical condition: Metastatic or unresectable renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003781-40 | Sponsor Protocol Number: GCT3014-01 | Start Date*: 2021-01-11 | ||||||||||||||||
Sponsor Name:Genmab A/S | ||||||||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies | ||||||||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Ongoing) ES (Ongoing) FR (Ongoing) NL (Ongoing) HU (Ongoing) CZ (Ongoing) PL (Ongoing) GR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.